Phathom

Discussion in 'Biotech Startups' started by anonymous, May 21, 2022 at 12:52 PM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    Totally agree with your point - but why punish the reps & take bonus away when it’s out of our control ?
     

  2. anonymous

    anonymous Guest

    It must be easy when you’re in a major metropolitan area, have speakers, have more than 10 GIs in your territory, had providers in the clinical trials, aren’t reliant on primary care with a limited label, etc….

    Don’t act like you’re “super rep” who generated all this volume on your own you douchebag. Just wait until we’re actually goaled based on geographic potential vs this one size fits all nonsense.

    My heart goes out to all the great talent who won’t make the money. I’ve met so many talented people who unfortunately don’t have favorable variables out the gate.

    This next call will be telling…make it right and PAY YOUR PEOPLE or this place will be a revolving door.

    To those poo-pooing on the ones who aren’t making the money - go fuck yourselves.
     
  3. anonymous

    anonymous Guest

    Amen. Extremely shortsighted of management
     
  4. anonymous

    anonymous Guest

    Management is horrible here.
     
  5. anonymous

    anonymous Guest

    I agree with the above post. My territory is predominantly GI and I have been lucky. I don’t think I’m a super rep, just a lucky one. I sincerely hope they do right by the sales force. It isn’t fair to treat territories the same.
     
  6. anonymous

    anonymous Guest

    Leadership is terrible and my manager is worse. This is a nightmare that i cant seem to wake up from.
     
  7. anonymous

    anonymous Guest

    I am fortunate in that my manager is pretty great, however they only have so much control. If Phathom cared to listen I’d say ..

    - Pay your sales force their bonus, regardless. Invest in your people in a launch.

    - Release all Blink RX data to the sales force daily/ weekly
    (none of this waiting til they have 5 unfilled RX’s, it’s too late then)

    - Do not mandate weekly team calls, let us sell.

    - Regularly seek feedback from your sales force & be willing to hear the good, bad and the ugly then adjust course

    - Allow for flexibility in call routing

    - Fix Veeva !

    - Be patient with RX’s. This is a process.
     
  8. anonymous

    anonymous Guest

    Treat your employees like an investment, not cost
     
  9. anonymous

    anonymous Guest

    Have faith you hired the right people- and treat them right.
     
  10. anonymous

    anonymous Guest

    Bottom line they could care less about the field force. Senior leaders over hired and they want people to leave.
     
  11. anonymous

    anonymous Guest

    Upper management acts as though they are all new to Pharma. All territories are not created equally as some in larger metro areas will have a deeper amount of commercial and Specialty Pharmacies that are willing to bypass Blink! I hope whoever is related to the Blink salesperson is happy - they have been a failure since day one and upper management doesn't want to admit it!
     
  12. anonymous

    anonymous Guest

    11 million short interest…wall street thinks this company will not have a happy ending
     
  13. anonymous

    anonymous Guest

    Phathom will probably be sold this year, Stringer is hinting at that. The market cap is low and once money gets tight it will be a cheap asset to acquire. It will take lots of cash and patience to get vono to blockbuster status and in 3-5 years there will be 2 or 3 other PCABs on the market. To fight off competition while you are still creating the PCAB market in the US is better done by a large pharma player with deep pockets. Japan shows the potential but Phathom just does not have coffers deep enough to get there alone. My two cents worth.

    If you consider s 50% acquisition premium the stock will ball around 15-17 in my opinion, maybe 20 so can make your calculations on the option pool.
     
  14. anonymous

    anonymous Guest

    Forgot to add - Try to stay employed by all means possible!
     
  15. anonymous

    anonymous Guest

    or the shorts have realized they can easily manipulate the share price given the low avg daily volume. Get back to work chump!
     
  16. anonymous

    anonymous Guest

    When you don't have Ron around to motivate/drive the sales force, you get big Pharma results.
     
  17. anonymous

    anonymous Guest

    The letter to shareholders indicates they want to expand into the gi space potentially
     
  18. anonymous

    anonymous Guest

  19. anonymous

    anonymous Guest

    I have enjoyed launching Voquenza. The response has been great. It is extremely frustrating having to use Blink. My success has come by bypassing this nightmare SP. The good news is we are getting close to being acquired by a real GI company. Takeda, Abbvie and a couple other GI companies are looking at us. We could get to blockbuster status in a few short years with the vision and support of a larger company with proper MC support. We all just need to hold on until better times arrive.